189 related articles for article (PubMed ID: 27643881)
1. Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Kim KM; Moon YJ; Park SH; Park HJ; Wang SI; Park HS; Lee H; Kwon KS; Moon WS; Lee DG; Kim JR; Jang KY
PLoS One; 2016; 11(9):e0163193. PubMed ID: 27643881
[TBL] [Abstract][Full Text] [Related]
2. Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
Park SH; Noh SJ; Kim KM; Bae JS; Kwon KS; Jung SH; Kim JR; Lee H; Chung MJ; Moon WS; Kang MJ; Jang KY
Transl Oncol; 2015 Aug; 8(4):239-49. PubMed ID: 26310369
[TBL] [Abstract][Full Text] [Related]
3. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Zhu Q; Han SX; Zhou CY; Cai MJ; Dai LP; Zhang JY
Oncotarget; 2015 May; 6(13):11575-84. PubMed ID: 25865228
[TBL] [Abstract][Full Text] [Related]
5.
Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
[TBL] [Abstract][Full Text] [Related]
6. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
7. PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.
Bertucci F; Finetti P; Monneur A; Perrot D; Chevreau C; Le Cesne A; Blay JY; Mir O; Birnbaum D
Mol Oncol; 2019 Jul; 13(7):1577-1588. PubMed ID: 31131495
[TBL] [Abstract][Full Text] [Related]
8. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
[TBL] [Abstract][Full Text] [Related]
9. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
Park HJ; Bae JS; Kim KM; Moon YJ; Park SH; Ha SH; Hussein UK; Zhang Z; Park HS; Park BH; Moon WS; Kim JR; Jang KY
J Exp Clin Cancer Res; 2018 May; 37(1):107. PubMed ID: 29784019
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
Okada S; Tokunaga E; Kitao H; Akiyoshi S; Yamashita N; Saeki H; Oki E; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 May; 19(5):1499-507. PubMed ID: 22179631
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Hybiak J; Domagala P; Domagala W
Pol J Pathol; 2018; 69(4):347-355. PubMed ID: 30786684
[TBL] [Abstract][Full Text] [Related]
12. Enhanced susceptibility of ovaries from obese mice to 7,12-dimethylbenz[a]anthracene-induced DNA damage.
Ganesan S; Nteeba J; Keating AF
Toxicol Appl Pharmacol; 2014 Dec; 281(2):203-10. PubMed ID: 25448685
[TBL] [Abstract][Full Text] [Related]
13. Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.
Wang X; Liu L; Montagna C; Ried T; Deng CX
Cell Death Differ; 2007 May; 14(5):924-31. PubMed ID: 17318223
[TBL] [Abstract][Full Text] [Related]
14. Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.
Bajrami I; Walker C; Krastev DB; Weekes D; Song F; Wicks AJ; Alexander J; Haider S; Brough R; Pettitt SJ; Tutt ANJ; Lord CJ
Commun Biol; 2021 Nov; 4(1):1270. PubMed ID: 34750509
[TBL] [Abstract][Full Text] [Related]
15. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
16. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
17. Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
Oei AL; Ahire VR; van Leeuwen CM; Ten Cate R; Stalpers LJA; Crezee J; Kok HP; Franken NAP
Int J Hyperthermia; 2018 Feb; 34(1):39-48. PubMed ID: 28540821
[TBL] [Abstract][Full Text] [Related]
18. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
[TBL] [Abstract][Full Text] [Related]
19. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
[TBL] [Abstract][Full Text] [Related]
20. TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells.
Fam HK; Walton C; Mitra SA; Chowdhury M; Osborne N; Choi K; Sun G; Wong PC; O'Sullivan MJ; Turashvili G; Aparicio S; Triche TJ; Bond M; Pallen CJ; Boerkoel CF
Mol Cancer Res; 2013 Oct; 11(10):1179-92. PubMed ID: 23913164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
